Condition: Fecal Microbiota Transplantation · Cesarean Section · Overweight and Obesity · Sponsor: Oulu University Hospital
This single-center randomized controlled trial evaluates whether donor-derived fecal microbiota transplantation (FMT) administered within 6 hours after birth can improve gut microbiota development and reduce the risk of immune-mediated and metabolic diseases in infants born by elective cesarean delivery. Newborns are randomized 1:1 to receive either donor-derived FMT or standard postnatal care. Participants are followed through 36 months of age with stool samples, questionnaires, growth assessments, and health data collection, with registry-based follow-up continuing until 10 years of age.
This description comes directly from the study's public registry record.
Marika Paalanne, MD, PhD · +358505794646 · marika.paalanne@oulu.fi
Terhi Ruuska-Loewald, Professor · +358505794420 · terhi.ruuska-loewald@oulu.fi
Always discuss trial participation with your own doctor first.
| Oulu University Hospital | Oulu, Finland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06282952